{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:03:36Z","timestamp":1778655816416,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Programme Hospitalier de Recherche Clinique national (Fr)","award":["2009"],"award-info":[{"award-number":["2009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13023-016-0411-5","type":"journal-article","created":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T05:01:02Z","timestamp":1458882062000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial"],"prefix":"10.1186","volume":"11","author":[{"given":"Christine","family":"Chiaverini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coralie","family":"Roger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Fontas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Bourrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Bourdon-Lanoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Labr\u00e8ze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Mazereeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Vabres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Bodemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Philippe","family":"Lacour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"411_CR1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.det.2009.10.020","volume":"28","author":"L Bruckner-Tuderman","year":"2010","unstructured":"Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: pathogenesis and clinical features. Dermatol Clin. 2010;28:107\u201314.","journal-title":"Dermatol Clin"},{"key":"411_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-013-0059-z","volume":"15","author":"CK Hsu","year":"2014","unstructured":"Hsu CK, Wang SP, Lee JY, et al. Treatment of hereditary epidermolysis bullosa: updates and future prospects. Am J Clin Dermatol. 2014;15:1\u20136.","journal-title":"Am J Clin Dermatol"},{"key":"411_CR3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/humu.20647","volume":"29","author":"M Titeux","year":"2008","unstructured":"Titeux M, Pendaries V, Tonasso L, et al. A frequent functional SNP in the MMP1 promoter is associated with higher disease severity in recessive dystrophic epidermolysis bullosa. Hum Mutat. 2008;29:267\u201376.","journal-title":"Hum Mutat"},{"key":"411_CR4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0006-291X(91)91518-H","volume":"174","author":"D Sawamura","year":"1991","unstructured":"Sawamura D, Sugawara T, Hashimoto I, et al. Increased gene expression of matrix metalloproteinase-3 (stromelysin) in skin fibroblasts from patients with severe recessive dystrophic epidermolysis bullosa. Biochem Biophys Res Commun. 1991;174:1003\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"411_CR5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1523-1747.2003.12325.x","volume":"121","author":"C Bodemer","year":"2003","unstructured":"Bodemer C, Tchen SI, Ghomrasseni S, et al. Skin expression of metalloproteinases and tissue inhibitor of metalloproteinases in sibling patients with recessive dystrophic epidermolysis and intrafamilial phenotypic variation. J Invest Dermatol. 2003;121:273\u20139.","journal-title":"J Invest Dermatol"},{"key":"411_CR6","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","volume":"82","author":"BN Singh","year":"2011","unstructured":"Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol. 2011;82:1807\u201321.","journal-title":"Biochem Pharmacol"},{"key":"411_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1389200214666131211155613","volume":"15","author":"G Hu","year":"2014","unstructured":"Hu G, Zhang L, Rong Y, et al. Downstream carcinogenesis signaling pathways by green tea polyphenols: a translational perspective of chemoprevention and treatment for cancers. Curr Drug Metab. 2014;15:14\u201322.","journal-title":"Curr Drug Metab"},{"key":"411_CR8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1017\/S0007114512006071","volume":"110","author":"LE Rhodes","year":"2013","unstructured":"Rhodes LE, Darby G, Massey KA, et al. Oral green tea catechin metabolites are incorporated into human skin and protect against UV radiation-induced cutaneous inflammation in association with reduced production of pro-inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid. Br J Nutr. 2013;110:891\u2013900.","journal-title":"Br J Nutr"},{"key":"411_CR9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/sj.jid.5700645","volume":"127","author":"SI Changotade","year":"2007","unstructured":"Changotade SI, Assoumou A, Gueniche F, et al. Epigallocatechin gallate\u2019s protective effect against MMP7 in recessive dystrophic epidermolysis bullosa patients. J Invest Dermatol. 2007;127:821\u20138.","journal-title":"J Invest Dermatol"},{"key":"411_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-8-69","volume":"8","author":"V Wally","year":"2013","unstructured":"Wally V, Kitzmueller S, Lagler F, et al. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study. Orphanet J Rare Dis. 2013;8:69.","journal-title":"Orphanet J Rare Dis"},{"key":"411_CR11","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2010.01.047","volume":"66","author":"I Lara-Corrales","year":"2012","unstructured":"Lara-Corrales I, Parkin PC, Stephens D, et al. The efficacy of trimethoprim in wound healing of patients with epidermolysis bullosa: a feasibility trial. J Am Acad Dermatol. 2012;66:264\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"411_CR12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJM199207163270305","volume":"327","author":"D Caldwell-Brown","year":"1992","unstructured":"Caldwell-Brown D, Stern RS, Lin AN, et al. Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med. 1992;327:163\u20137.","journal-title":"N Engl J Med"},{"key":"411_CR13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1046\/j.1365-2133.2004.05816.x","volume":"150","author":"M Weiner","year":"2004","unstructured":"Weiner M, Stein A, Cash S, et al. Tetracycline and epidermolysis bullosa simplex: a double-blind, placebo-controlled, crossover randomized clinical trial. Br J Dermatol. 2004;150:613\u20134.","journal-title":"Br J Dermatol"},{"key":"411_CR14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/ijd.12499","volume":"53","author":"J Garza-Gomez","year":"2014","unstructured":"Garza-Gomez J, Cerda-Flores RM, Gomez-Flores M, et al. An investigation into the MMP1 gene promoter region polymorphism--1607 2G with recessive dystrophic epidermolysis bullosa disease severity in northeastern Mexican patients. Int J Dermatol. 2014;53:985\u201390.","journal-title":"Int J Dermatol"},{"key":"411_CR15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/j.1365-2133.2009.09333.x","volume":"161","author":"JS Kern","year":"2009","unstructured":"Kern JS, Gruninger G, Imsak R, et al. Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort. Br J Dermatol. 2009;161:1089\u201397.","journal-title":"Br J Dermatol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-016-0411-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T09:17:47Z","timestamp":1498295867000},"score":1,"resource":{"primary":{"URL":"http:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-016-0411-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["411"],"URL":"https:\/\/doi.org\/10.1186\/s13023-016-0411-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,25]]},"article-number":"31"}}